Antiphospholipid antibodies mediate autoimmunity against dying cells

Area of Science:

• Immunology
• Autoimmunity
• Pathophysiology

Background:

• Antiphospholipid Syndrome (APS) is defined by thrombosis and pregnancy loss.
• Pathogenic anti-phospholipid autoantibodies (aPL) mediate these clinical events.
• Beta-2-glycoprotein I (β2GPI) is a primary autoantigen for aPL.

Purpose of the Study:

• To elucidate the dual role of apoptotic cells in Antiphospholipid Syndrome (APS).
• To understand the mechanisms of aPL induction and disease chronification.
• To explore the contribution of β2GPI and dying cells in APS pathogenesis.

Main Methods:

• Conceptual analysis of immune mechanisms in APS.
• Review of literature on β2GPI, apoptotic cells, and autoantibody production.
• Exploration of factors influencing APS clinical phenotypes.

Main Results:

• Dying cells decorated with β2GPI can induce pathogenic aPL via antigen-presenting cell uptake and T cell activation.
• These β2GPI-coated apoptotic bodies can be targeted by aPL, promoting pro-inflammatory macrophage activity.
• Epitope spreading can lead to autoimmunity against nuclear autoantigens, contributing to disease progression.

Conclusions:

• Apoptotic cells serve a dual role in APS: as initial immunogens (etiology) and as targets for inflammation chronification (pathology).
• Genetic background and cytokine milieu, particularly type I interferons, influence disease evolution.
• Factors like β2GPI domain specificity modulate the pathogenicity of aPL and clinical outcomes.